IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New antibody drug aims to control kidney disease
Disease control Recruiting nowThis study tests a new drug called MIL116 in healthy volunteers and people with IgA nephropathy, a kidney disease. The drug targets a protein to reduce kidney damage. The goal is to check safety and how well it works over several weeks.
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Beijing Mabworks Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:23 UTC
-
New hope for kids with rare kidney diseases: sparsentan trial launches
Disease control Recruiting nowThis study tests an experimental drug called sparsentan in 67 children with certain kidney diseases that cause protein leakage in urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants take the drug once daily as a liquid or tablet, and r…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 05:04 UTC
-
New hope for kids with kidney disease: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage, and help control the disease. Participants will receive the drug through an I…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 04:34 UTC
-
Promising drug aims to shield kidneys from IgA nephropathy attack
Disease control Recruiting nowThis study tests whether ravulizumab can reduce protein in urine and preserve kidney function in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either the drug or a placebo. The goal is to see if the drug slows disease …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New drug iptacopan tested to see if it repairs kidney damage in rare disease
Knowledge-focused Recruiting nowThis study looks at how iptacopan affects the kidneys of 20 adults with IgA nephropathy, a kidney disease. Researchers will measure changes in kidney tissue and function over 9 months. The goal is to understand if the drug reduces immune system activity in the kidneys.
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 05:07 UTC